Tech Company Inital Public Offerings
Immunome IPO
Based in Exton, Immunome is now a public company.
Transaction Overview
Company Name
Announced On
10/1/2020
Transaction Type
IPO
Amount
$39,000,000
Proceeds Purpose
Management says it will use the net proceeds from the IPO as follows:approximately $6.5 million to fund further development of our IMM-ONC-01 program;approximately $5.8 million to fund further development of our IMM-BCP-01 program;approximately $5.9 million to advance our platform and research pipeline; andthe remainder to fund other research and development activities, working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
665 Stockton Dr. 300
Exton, PA 19341
USA
Exton, PA 19341
USA
Phone
Website
Email Address
Overview
Immunome (Nasdaq: IMNM) is a biopharmaceutical company with a patented native, human antibody platform which enables us to harness the natural curative power of the human immune system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Purnanand Sarma
Chief Scientific Officer
Michael Morin
Co-Founder
Scott Dessain
VP - Bus. Development
Karen Lundgren
VP - Engineering
Pavel Nikitin
VP - R & D
Lauren Pitt
VP - R & D
Matthew Robinson
Browse more venture capital transactions:
Prev: 10/1/2020: Bloomscape venture capital transaction
Next: 10/1/2020: Siren venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs